CAR T-cell therapy generates lasting remissions in patients with multiple myeloma

In a major advance in the treatment of multiple myeloma, a CAR T-cell therapy has generated deep, sustained remissions in patients who had relapsed from several previous therapies, an international clinical trial has found.

Read more

CAR T cell therapy effective as first-line treatment for high-risk large B-cell lymphoma

A study led by researchers at The University of Texas MD Anderson Cancer Center found that axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, is a safe and effective first-line therapy for patients with high-risk large B-cell lymphoma (LBCL), a group with an urgent need for new and effective treatments.

Read more

CAR T-cell therapy found highly effective in patients with high-risk non-Hodgkin lymphoma

A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial, Dana-Farber Cancer Institute investigators report at the virtual 62nd American Society of Hematology (ASH) Annual Meeting.

Read more

Dana-Farber to present more than 40 research studies at 2020 ASH Annual Meeting

Dana-Farber Cancer Institute researchers will present more than 40 research studies at the virtual 62nd American Society of Hematology (ASH) Annual Meeting on December 5-8, including two studies that were selected for inclusion in the official press program.

Read more

Fred Hutch at ASH: Fauci fireside chat, latest on cell therapies, repairing immune function, COVID and clots — and more

SEATTLE — Nov. 18, 2020 — Fred Hutchinson Cancer Research Center’s latest findings on cell therapies, repairing immune function, and more will be featured at the 62nd American Society of Hematology Annual Meeting & Exposition, to be held virtually Dec. 5 – 8.Dr. Stephanie Lee, ASH president and Fred Hutch physician-scientist will kick off the meeting with a fireside chat with Dr.

Read more

Dana-Farber to offer first CAR T-cell therapy for mantle cell lymphoma following FDA approval

Today’s Food and Drug Administration (FDA) approval of the first CAR T-cell therapy for mantle cell lymphoma (MCL) represents a key advance for patients with relapsed or treatment-resistant forms of the disease, say Dana-Farber Cancer Institute investigators who helped conduct the decisive clinical trial of the therapy.

Read more

2 immunotherapies merged into single, more effective treatment

Researchers at Washington University School of Medicine in St. Louis have combined two immunotherapy strategies into a single therapy and found, in studies in human cells and in mice, that the two together are more effective than either alone in treating certain blood cancers, such as leukemia.

Read more

Moffitt Researchers Identify Factors to Predict Severe Toxicities in CAR T Patients

In a new study published in Clinical Cancer Research, Moffitt Cancer Center researchers identify possible factors that could help physicians know if patients are at higher risk for severe adverse events before they receive CAR T therapy.

Read more

NCCN: What People with Cancer and their Caregivers Need to Know about CAR T-Cell Therapy

The National Comprehensive Cancer Network (NCCN) has published a new NCCN Guidelines for Patients: Immunotherapy Side Effects focused on chimeric antigen receptor (CAR) T-cell therapy. This is book two in a series that includes another book on irAEs focused on immune checkpoint inhibitors.

Read more